Analyst Update: 3D Systems Corporation, Gilead Sciences, Inc., and Halozyme Therapeutics, Inc.

Analysts adjusted their ratings on 3D Systems Corporation (DDD), Gilead Sciences, Inc. (GILD), and Halozyme Therapeutics, Inc. (HALO).

by Mark Fightmaster

Published on Jul 9, 2015 at 2:02 PM
Updated on Jul 9, 2015 at 2:03 PM

Analysts are weighing in today on 3-D printing pioneer 3D Systems Corporation (NYSE:DDD), as well as biotechs Gilead Sciences, Inc. (NASDAQ:GILD) and Halozyme Therapeutics, Inc. (NASDAQ:HALO).  Here's a quick look at today's brokerage notes on DDD, GILD, and HALO.

  • This morning, Piper Jaffray announced that it dropped its price target on DDD to $16 from $18 and that it issued an "underweight" rating on the firm. The analysts also stated that, while they expect the industry to bounce back in 2016, DDD "will continue to struggle given execution issues, product quality concerns, channel headwinds, and overly aggressive consensus forecasts." DDD is more than 6.8% lower at $16.41, and just off a three-year low of $16.35, bucking the broad-market rally. DDD continues to have an impressive amount of its float sold short, something that caught our eye last week. Analysts agree with this bearish sentiment, as 15 of the 18 analysts tracking 3D Systems Corporation rate it a "hold" or worse. 
  • GILD is 0.8% higher at $113.89, as biotechs rally and thanks to UBS upping its price target from $125 to $133 -- in uncharted territory. The brokerage also underscored a "buy" rating on Gilead Sciences, Inc. Technically, GILD is a solid performer, but has pulled back since hitting an all-time high in late June. This technical slide may have caught the eyes of options players last week, as puts were bought to open at a faster clip than calls. This bearish action is belied by analysts, as 14 of the 16 tracking GILD rate it a "buy" or better. 
  • HALO saw its price target lifted to $28 from $21 -- in record-high territory -- at UBS today. Thanks to today's news and a sector rally, Halozyme Therapeutics, Inc. is nearly 7% higher at $22.81. Technically speaking, HALO has more than doubled in 2015. While the biotech is sparsely covered by analysts, there is a good chance for a short-covering rally, as more than 16% of its float is sold short. Should today's news spook the shorts, it would take eight days for the bears to cover their shorted shares, at HALO's average pace of trading.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.
Zoom Stock Brushes Off Senate Warning
The U.S. Senate just warned its members against using Zoom as a video chat platform
Costco Stock Dips on Bear Note
Deutsche Bank cut its price target to $295 from $300
The Top Lithium Play of 2020
Click to continue to advertiser's site.